[New tracers and combinations in radioligand therapy for prostate cancer]. / Neue Tracer und Kombinationen bei der Radioligandentherapie des Prostatakarzinoms.
Urologie
; 62(7): 691-695, 2023 Jul.
Article
em De
| MEDLINE
| ID: mdl-37318583
ABSTRACT
BACKGROUND:
177Lutetium radioligand therapy directed against the prostate-specific membrane antigen (PSMA) is a new approved option for the treatment of metastatic, castration-resistant prostate cancer associated with a favorable toxicity profile.OBJECTIVES:
What are new or emerging developments in radioligand therapy for prostate cancer? MATERIALS ANDMETHODS:
A review of the current literature was performed.RESULTS:
The further development of radioligand therapy for prostate cancer is currently taking place primarily in the following areas application in earlier stages of the disease, use of alternative isotopes, development and use of new ligands, search for new target structures and combination with other forms of therapy.CONCLUSIONS:
Radioligand therapy has become an integral part of the therapy algorithm in the treatment of metastatic, castration-resistant prostate cancer. Application in earlier stages of the disease is foreseeable. In the future, new ligands, alternative isotopes, new targets or combination therapies may increase efficacy and reduce toxicity.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias de Próstata Resistentes à Castração
Limite:
Humans
/
Male
Idioma:
De
Ano de publicação:
2023
Tipo de documento:
Article